BioVie Invited to Present Data on Bezisterim at NIH's RECOVER-TLC Workshop
BioVie Inc. has been invited to present clinical data on its investigational therapy, bezisterim, at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.
Stocks · News reference
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out yesterday.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioVie shares are trading higher after the company announced the presentation of Phase 2 Long COVID data showing statistically significant improvements in fatigue and cognitive measures in certain patient subgroups treated with bezisterim.
BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of
BioVie To Present Phase 2 Bezisterim Data In Long COVID, Parkinson’s At Neurology Conference October 18-19
8-K filing — CIRCLE8 GROUP INC (CIRC)
Filed: 2026-10-23 AccNo: 0001605888-26-000054 Size: 153 KB Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Item 9.01: Financial Statements and Exhibits
Circle8 Group shares are trading higher after the company announced it was awarded a CAK managed services contract.